ALT-B8

N/A

Report date: 2022/11/29 15:26:38

Base Information

Drug NameALT-B8
Drug Alias NameLong-acting GLP1-Fc-FGF19ALT-B8
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsFibroblast growth factor 19 modulators
TargetsGlucagon-like peptide 1 receptorFibroblast growth factor 19
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlteogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlteogen Inc
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A